RAPT Therapeutics (RAPT) Common Equity: 2020-2024
Historic Common Equity for Therapeutics (RAPT) over the last 5 years, with Sep 2024 value amounting to $95.5 million.
- Therapeutics' Common Equity fell 44.73% to $95.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $95.5 million, marking a year-over-year decrease of 44.73%. This contributed to the annual value of $147.0 million for FY2023, which is 40.03% down from last year.
- According to the latest figures from Q3 2024, Therapeutics' Common Equity is $95.5 million, which was down 12.56% from $109.2 million recorded in Q2 2024.
- Therapeutics' Common Equity's 5-year high stood at $245.2 million during Q4 2022, with a 5-year trough of $91.6 million in Q1 2021.
- For the 3-year period, Therapeutics' Common Equity averaged around $170.9 million, with its median value being $172.8 million (2023).
- Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 83.44% in 2021, then crashed by 45.30% in 2024.
- Over the past 5 years, Therapeutics' Common Equity (Quarterly) stood at $104.2 million in 2020, then skyrocketed by 78.90% to $186.4 million in 2021, then surged by 31.54% to $245.2 million in 2022, then crashed by 40.03% to $147.0 million in 2023, then tumbled by 44.73% to $95.5 million in 2024.
- Its last three reported values are $95.5 million in Q3 2024, $109.2 million for Q2 2024, and $130.8 million during Q1 2024.